Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 16/20 | 0.52 |
| ▸ | THRA | P10827 | 13/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.34 |
| ▸ | FEN1 | P39748 | 4/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28651241 | 0.96 | THRB (0.51) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL28442792 | 0.95 | THRB (0.56) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL28651291 | 0.85 | THRB (0.52) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL23260089 | 0.84 | THRB (0.47) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL28651437 | 0.84 | THRB (0.51) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL29417471 | 0.84 | THRB (0.52) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632380 | 0.81 | THRB (0.66) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL25871576 | 0.80 | THRB (0.45) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632702 | 0.79 | THRB (0.66) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22632404 | 0.78 | THRB (0.65) | THRBTHRACYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4523692-A2 | MODULATORS OF THR-SS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3965884-B1 | MODULATORS OF THR-BETA WITH A DIOXO-1,2,4-TRIAZYL HEAD GROUP | ALIGOS THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20230167091-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | Shandong First Medical University & Shandong Academy Of Medical Sciences (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2022127779-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | 山东第一医科大学(山东省医学科学院) | 2022-06-23 | — | — | WO | disclosed |
| EP-3965884-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114096531-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | THRB 1/4885THRA 2/4885CYP2C9 3471/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | THRB 1/4885THRA 2/4885CYP2C9 3117/4885 |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | THRB 1/4885THRA 2/4885CYP2C9 3471/4885 |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | THRB 1/4885THRA 2/4885CYP2C9 3457/4885 |
| US-20230167091-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | THRB, TPO, TSHR | THRB 1/4885THRA 4/4885CYP2C9 379/4885 |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | THRB 1/4885THRA 2/4885CYP2C9 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.